MedTrace Logo

Phase Ⅱc Sutdy of Aolanti Weikang Tablets in FD PDS Patients

NCT03971383 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 236

Last updated 2019-06-03

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and validity of Aolanti Weipang Tablets in Patients with Postprandial Discomfort Syndrome of Functional Dyspepsia

Conditions

  • Functional Dyspepsia

Interventions

DRUG

Aolanti Weipang Tablets

3 tablets one time, 3 times a day(tid)

DRUG

Placebo

3 tablets one time, 3 times a day(tid)

Sponsors & Collaborators

  • Jiangxi Qingfeng Pharmaceutical Co. Ltd.

    lead INDUSTRY

Principal Investigators

  • Xiao Ke · The Second People's Hospital of Fujian Province

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-10
Primary Completion
2020-10-31
Completion
2021-05-03

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03971383 on ClinicalTrials.gov